Mark L Hartman

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Venues

Nature medicine

Alimentary pharmacology & therapeutics

Diabetes care

Eli Lilly and Company

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Eli Lilly and Company Jan 05 1998

United States

Medical Fellow :: Clinical Research - Diabetes and Complications

Publications

Arun J Sanyal, Lee M Kaplan, Juan P Frias, Bram Brouwers, Qiwei Wu, Melissa K Thomas, Charles Harris, Nanette C Schloot, Yu Du, Kieren J Mather, Axel Haupt, Mark L Hartman
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine 30 (7) (2024)
Raj K Vuppalanchi, Stephen Caldwell, Arun J Sanyal, Amir Nikooie, Yuanyuan Tang, Deborah A Robins, Bram Brouwers, Mark L Hartman
Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures. Alimentary pharmacology & therapeutics (2024)
Raj K Vuppalanchi, Stephen Caldwell, Arun J Sanyal, Amir Nikooie, Yuanyuan Tang, Deborah A Robins, Bram Brouwers, Mark L Hartman
Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures. Alimentary pharmacology & therapeutics 60 (1) (2024)
Arun J Sanyal, Lee M Kaplan, Juan P Frias, Bram Brouwers, Qiwei Wu, Melissa K Thomas, Charles Harris, Nanette C Schloot, Yu Du, Kieren J Mather, Axel Haupt, Mark L Hartman
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine (2024)
Arun J Sanyal, Lee M Kaplan, Juan P Frias, Bram Brouwers, Qiwei Wu, Melissa K Thomas, Charles Harris, Nanette C Schloot, Yu Du, Kieren J Mather, Axel Haupt, Mark L Hartman
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine 30 (7) (2024)
Arun J Sanyal, Lee M Kaplan, Juan P Frias, Bram Brouwers, Qiwei Wu, Melissa K Thomas, Charles Harris, Nanette C Schloot, Yu Du, Kieren J Mather, Axel Haupt, Mark L Hartman
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine 30 (7) (2024)
Raj K Vuppalanchi, Stephen Caldwell, Arun J Sanyal, Amir Nikooie, Yuanyuan Tang, Deborah A Robins, Bram Brouwers, Mark L Hartman
Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures. Alimentary pharmacology & therapeutics 60 (1) (2024)
Arun J Sanyal, Lee M Kaplan, Juan P Frias, Bram Brouwers, Qiwei Wu, Melissa K Thomas, Charles Harris, Nanette C Schloot, Yu Du, Kieren J Mather, Axel Haupt, Mark L Hartman
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine (2024)
Arun J Sanyal, Lee M Kaplan, Juan P Frias, Bram Brouwers, Qiwei Wu, Melissa K Thomas, Charles Harris, Nanette C Schloot, Yu Du, Kieren J Mather, Axel Haupt, Mark L Hartman
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine 30 (7) (2024)
Arun J Sanyal, Lee M Kaplan, Juan P Frias, Bram Brouwers, Qiwei Wu, Melissa K Thomas, Charles Harris, Nanette C Schloot, Yu Du, Kieren J Mather, Axel Haupt, Mark L Hartman
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine (2024)
Raj K Vuppalanchi, Stephen Caldwell, Arun J Sanyal, Amir Nikooie, Yuanyuan Tang, Deborah A Robins, Bram Brouwers, Mark L Hartman
Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures. Alimentary pharmacology & therapeutics 60 (1) (2024)
Mark L Hartman, Arun J Sanyal, Rohit Loomba, Jonathan M Wilson, Amir Nikooienejad, Ross Bray, Chrisanthi A Karanikas, Kevin L Duffin, Deborah A Robins, Axel Haupt
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. Diabetes care 43 (6) (2020)

Mark L Hartman.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Mark L Hartman